A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma
Study sponsor: Agenus Inc. · AGEN
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2005-06Actual
Enrollment · participants35
Source updated2023-09-28Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.